Compass Therapeutics (CMPX) Research & Development (2019 - 2026)
Compass Therapeutics recorded quarterly Research & Development of $13.4 million in Q1 2026, down 2.06% quarter-over-quarter from $13.7 million in Q4 2025, and up 2.57% year-over-year from $13.1 million in Q1 2025.
Compass Therapeutics' Research & Development history runs 8 years deep, the most recent figure standing at $13.4 million for Q1 2026.
- In Q1 2026, Research & Development rose 2.57% year-over-year to $13.4 million; the TTM figure through Mar 2026 stood at $56.3 million (up 22.72% YoY), while the FY2025 annual figure was $56.0 million, up 32.18% from the prior year.
- Research & Development came in at $13.4 million for Q1 2026 at Compass Therapeutics, down from $13.7 million in the prior quarter.
- In the past five years, Research & Development ranged from a high of $16.4 million in Q2 2025 to a low of $4.4 million in Q1 2022.
- A 5-year average of $10.6 million and a median of $10.2 million in 2023 frame the typical range for Research & Development.
- Across the five-year window, Research & Development jumped 210.43% in 2022 and decreased 9.8% in 2023, its largest moves.
- Compass Therapeutics' Research & Development stood at $9.9 million in 2022, then increased by 25.16% to $12.4 million in 2023, then increased by 4.93% to $13.0 million in 2024, then advanced by 4.86% to $13.7 million in 2025, then decreased by 2.06% to $13.4 million in 2026.
- According to Business Quant data, Research & Development over the past three periods registered $13.4 million, $13.7 million, and $12.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 626,092.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 4.32 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -101.30 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 1.46 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 961.60 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -2.30 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 1.54 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 364.87 Mn |
| 10 | Compass Therapeutics | 418.47 Mn | 223.78 Mn | - | 13.39 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 13.39 Mn |
| Dec 31, 2025 | 13.67 Mn |
| Sep 30, 2025 | 12.83 Mn |
| Jun 30, 2025 | 16.42 Mn |
| Mar 31, 2025 | 13.05 Mn |
| Dec 31, 2024 | 13.04 Mn |
| Sep 30, 2024 | 8.61 Mn |
| Jun 30, 2024 | 11.17 Mn |
| Mar 31, 2024 | 9.52 Mn |
| Dec 31, 2023 | 12.43 Mn |
| Sep 30, 2023 | 8.83 Mn |
| Jun 30, 2023 | 10.22 Mn |
| Mar 31, 2023 | 6.64 Mn |
| Dec 31, 2022 | 9.93 Mn |
| Sep 30, 2022 | 9.79 Mn |
| Jun 30, 2022 | 5.86 Mn |
| Mar 31, 2022 | 4.42 Mn |
| Dec 31, 2021 | 9.57 Mn |
| Sep 30, 2021 | 3.15 Mn |
| Mar 31, 2021 | 4.70 Mn |
| Sep 30, 2020 | 3.67 Mn |
| Jun 30, 2020 | 2.99 Mn |
| Mar 31, 2020 | 3.57 Mn |
| Sep 30, 2019 | 5.98 Mn |
| Jun 30, 2019 | 5.39 Mn |